Cholangiocarcinoma — novel biological insights and therapeutic strategies
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/05/15
-
Journal
-
Indian UGC (journal)
-
Refrences161
-
Citations23
-
Sumera I. Ilyas
-
Silvia Affo
-
Lipika Goyal
-
Angela Lamarca
-
Gonzalo Sapisochin
-
Ju Dong Yang ORCID (unauthenticated)
-
Gregory J. Gores ORCID (unauthenticated)
Cite
Ilyas, Sumera I., et al. “Cholangiocarcinoma — Novel Biological Insights and Therapeutic Strategies”. Nature Reviews Clinical Oncology, vol. 20, no. 7, 2023, pp. 470-86, https://doi.org/10.1038/s41571-023-00770-1.
Ilyas, S. I., Affo, S., Goyal, L., Lamarca, A., Sapisochin, G., Yang, J. D., & Gores, G. J. (2023). Cholangiocarcinoma — novel biological insights and therapeutic strategies. Nature Reviews Clinical Oncology, 20(7), 470-486. https://doi.org/10.1038/s41571-023-00770-1
Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma — novel biological insights and therapeutic strategies. Nature Reviews Clinical Oncology. 2023;20(7):470-86.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| 10.1200/JCO.2022.40.16_suppl.4075 | 2022 | |||
| 10.1200/JCO.2022.40.16_suppl.4006 | 2022 | |||
| 10.1200/JCO.2022.40.4_suppl.461 | 2022 | |||
| 10.1200/JCO.2022.40.16_suppl.4070 | 2022 | |||
| 93P Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study | Annals of Oncology |
| 1 | 2022 |
Refrences Analysis
The category
Medicine: Medicine (General) 58
is the most frequently represented among the references in this article. It primarily includes studies from Journal of Hepatology The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma | Current Treatment Options in Oncology |
| 2024 | |
| Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide | Biomedicine & Pharmacotherapy |
| 2024 | |
| Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma | Cellular and Molecular Gastroenterology and Hepatology |
| 1 | 2024 |
| Trailblazing TRAIL Therapy: Illuminating Pathways for Cholangiocarcinoma Treatment | Cellular and Molecular Gastroenterology and Hepatology |
| 2024 | |
| Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma | Journal of Hepatology |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 17
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Targeting polycomb repressor complex 2‐mediated bivalent promoter epigenetic silencing of secreted frizzled‐related protein 1 inhibits cholangiocarcinoma progression and was published in 2023. The most recent citation comes from a 2024 study titled N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1. This article reached its peak citation in 2024, with 16 citations. It has been cited in 19 different journals, 26% of which are open access. Among related journals, the Journal of Experimental & Clinical Cancer Research cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.